We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Hotgen Showcases Innovative Immunodiagnostic Solutions at ADLM 2026

By LabMedica International staff writers
Posted on 28 Jul 2026

Beijing Hotgen Biotech (Beijing, China) is participating in the ADLM 2026 Clinical Lab Expo, taking place July 28–30 in Anaheim, California. More...

At booth 4020, the company is presenting immunodiagnostic solutions designed to support accurate and efficient testing across clinical laboratories and other healthcare settings.

Hotgen’s portfolio is built around eight proprietary technology platforms and centers on chemiluminescence immunoassay systems, complemented by point-of-care and rapid testing products. The company is highlighting solutions intended to address different testing volumes and clinical applications, from centralized laboratories to emergency and primary care environments.

Among the featured products is the MQ60 Series Mono-test Chemiluminescence Immunoassay System. The platform supports a menu of more than 130 testing parameters and has accumulated over 18,000 installations worldwide. It is designed to provide accurate and efficient immunodiagnostic testing for laboratories of different sizes.

Hotgen is also showcasing its C800 and C2100 Series Chemiluminescence Immunoassay Systems. The automated platforms are designed to accommodate the testing requirements of healthcare institutions with different workload levels while providing flexible and reliable chemiluminescence immunoassay workflows.

For point-of-care applications, the company is presenting the UPT2800 testing system, which is powered by Hotgen’s proprietary Up-converting Phosphor Technology. The portable platform is designed to deliver rapid and accurate results for applications including primary healthcare, emergency diagnostics, and public health testing.

The company’s infectious disease portfolio at the event includes its TB-IGRA tuberculosis infection detection solution. Designed to support tuberculosis infection screening and clinical auxiliary diagnosis, the system provides testing capabilities for tuberculosis prevention and control programs. Hotgen is additionally exhibiting colloidal gold rapid tests and enzyme-linked immunosorbent assay products for a broader range of diagnostic applications.

Founded in 2005, Hotgen currently supplies products to more than 50 countries and regions. Its solutions have received international certifications, including European Union certification under the In Vitro Diagnostic Medical Devices Regulation, supporting their adoption across global immunodiagnostic markets.


Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
Multi-Chamber Washer-Disinfector
WD 390
New
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Pathology

view channel
Image: Agilent’s PD-L1 IHC 22C3 pharmDx has received EU certification as a companion diagnostic to identify PD-L1–positive ovarian, fallopian tube, or primary peritoneal carcinoma patients eligible for KEYTRUDA (Photo courtesy of Agilent)

PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.